Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Calcium Channel Blockade in Primary Aldosteronism

NCT04179019 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT04179019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Calcium Channel Blockade in Primary Aldosteronism
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2020
Completion date
December 30, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary aldosteronism, primary aldosteronism due to adrenal hyperplasia (bilateral)